Compare AUROW & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUROW | TGTX |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | United States |
| Employees | 1800 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 5.5B |
| IPO Year | N/A | 1995 |
| Metric | AUROW | TGTX |
|---|---|---|
| Price | $0.28 | $30.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $54.75 |
| AVG Volume (30 Days) | 137.0K | ★ 1.6M |
| Earning Date | 04-30-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $531,898,000.00 |
| Revenue This Year | N/A | $87.88 |
| Revenue Next Year | N/A | $48.75 |
| P/E Ratio | ★ N/A | $11.21 |
| Revenue Growth | N/A | ★ 100.88 |
| 52 Week Low | $2.09 | $25.28 |
| 52 Week High | $3.00 | $46.48 |
| Indicator | AUROW | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 41.29 |
| Support Level | $0.28 | $30.40 |
| Resistance Level | $0.34 | $32.30 |
| Average True Range (ATR) | 0.03 | 1.10 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 21.86 | 22.12 |
Aurora Innovation Inc delivers self-driving technology safely, quickly, and broadly. The Aurora Driver is a self-driving system designed to operate multiple vehicle types, from freight-hauling trucks to ride-hailing passenger vehicles. It underpins Aurora Horizon and Aurora Connect, its driver-as-a-service products for trucking and ride-hailing. The Company is developing the Aurora Driver, a scalable suite of self-driving hardware, software, and data services designed as a platform to adapt and interoperate among vehicle types and applications.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.